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Abstract
Introduction: Pancreatitis is a rare manifestation of cystic fibrosis (CF) and may rarely be the
presenting symptom in adolescent or adult patients with CF. We report a case of a 4 year-old
female who initially presented with recurrent pancreatitis, a normal sweat test, and a diagnosis of
pancreas divisum. She was subsequently diagnosed with cystic fibrosis at the age of 6 years, despite
normal growth and no pulmonary symptoms, after nasal potential difference measurements
suggested possible CF and two known CF-causing mutations (ΔF508 and L997F) were detected.
Case Presentation: An otherwise healthy 4 year-old female developed chronic pancreatitis and
was diagnosed with pancreas divisum. Sphincterotomy was performed without resolution of her
pancreatitis. Sweat test was negative for cystic fibrosis, but measurement of nasal potential
differences suggested possible cystic fibrosis. These results prompted extended Cystic Fibrosis
Transmembrane Regulator Conductance (CFTR) mutational analysis that revealed a compound
heterozygous mutation: ΔF508 and L997F.
Conclusion: CFTR mutations should be considered in cases of chronic or recurrent pancreatitis
despite a negative sweat test and the presence of pancreas divisum. Children with CFTR mutations
may present with recurrent pancreatitis, lacking any other signs or symptoms of cystic fibrosis. It
is possible that the combination of pancreas divisum and abnormal CFTR function may contribute
to the severity and frequency of recurrent pancreatitis.
Introduction
Pancreatitis is a rare manifestation of cystic fibrosis, affect-
ing < 2% of patients with CF. Pancreatitis may be the pre-
senting symptom in adolescent or adult patients with
mild CF. We report a case of a 4 year-old female who ini-
tially presented with recurrent pancreatitis, pancreas
divisum, and a normal sweat test. She was subsequently
diagnosed with cystic fibrosis at the age of 6 years, despite
normal growth and no pulmonary symptoms, after nasal
potential difference measurements suggested possible CF
and two known CF-causing mutations (ΔF508 and
L997F) were detected (Table 1). In patients with CF pan-
creatitis, sweat chloride levels are often normal and even
nasal potential differences may reveal only subtle abnor-
malities. Recurrent pancreatitis in children should raise
suspicion for cystic fibrosis, despite a normal sweat test or
a known diagnosis of pancreas divisum.
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Case presentation
A 4 year-old female presented with a two-month history
of recurrent episodes of pancreatitis. Her clinical symp-
toms were diffuse, episodic abdominal pain in the
absence of vomiting, weight loss, fevers or joint pain.
Stools were described as bulky and green. On physical
examination of the abdomen, there was mild tenderness
in the epigastrium, but no peritoneal signs nor hepat-
osplenomegaly. At the time of initial presentation, the
patient's serum lipase and amylase were >30,000 U/L and
>18,000 U/L, respectively. The remainder of her labora-
tory workup was normal, including serum cholesterol and
triglycerides. An abdominal ultrasound showed a hypere-
choic pancreas consistent with pancreatitis, and a hepato-
biliary system that appeared normal. The patient received
supportive care, including bowel rest and hydration, and
was ultimately discharged on a low fat diet once her serum
amylase and lipase normalized. Her previous investiga-
tions included a normal sweat chloride test and a normal
endoscopic retrograde cholangiopancreatography
(ERCP).
The patient was subsequently readmitted one month later
with another episode of clinical pancreatitis. On examina-
tion of her previous ERCP images, the possibility of short
ventral duct was suspected and a repeat ERCP demon-
strated pancreatic duct divisum. She underwent minor
papilla sphincterotomy and pancreatic duct stent place-
ment. Despite the sphincterotomy, she was again readmit-
ted to hospital on three separate occasions over 12
months with clinical and biochemical pancreatitis,
prompting the institution of pancreatic enzyme supple-
mentation with meals and snacks.
Cystic fibrosis (CF) was suspected, but sweat chloride was
23 mEq/L and a CF gene mutation analysis was positive
for only one copy of the ΔF508 mutation. She then under-
went nasal potential difference measurements. Mean
baseline potential difference was -28 mV (range -21 to -35
mV). Superfusion of amiloride to lower the sodium
potential blocked 55% of the potential difference, and
was within normal limits. The low chloride and isoproter-
enol responses were equivocal, but suggestive of CF,
thereby raising concerns for an unidentified CF mutation
on the second allele. (Figure 1, Chart 1) [1].
Extended Cystic Fibrosis Transmembrane Receptor
(CFTR) mutation analysis showed that the patient was
positive for the L997F mutation in addition to the ΔF508,
both known cystic fibrosis-causing mutations. She had no
respiratory complaints and had repeated pulmonary func-
tion testing that was normal. Interestingly, her father is of
Irish ancestry and her mother is of Maltese descent. Both
were shown to carry a CF mutation, the mother carrying
the more obscure L997F mutation. Three of four siblings
were later found to carry one or the other mutation and
remain healthy.
Discussion
Cystic fibrosis (CF) is a common inherited and clinically
heterogenous multisystemic disorder that affects glands
and secretory epithelia. Although most patients have
chronic lung disease and pancreatic insufficiency, 20% of
patients are able to digest and absorb fat normally, and as
a consequence are at risk for recurrent pancreatitis. In this
unique patient population, pancreatitis is frequently the
clinical presentation that leads to the diagnosis of CF.
Table 1: Nasal potential difference measurements at basal, change after amiloride, chloride, and isoproteronol infusions. Results were 
suggestive of possible cystic fibrosis.
NORMAL CF Pt's Left Nare Pt's Right Nare
Basal (mV) 18.2 ± 8.3 -45 ± 11 -21 -35
Δ Amiloride 10.5 ± 6 29.8 ± 11 9 33
Δ Low Chloride -14.1 ± 9 2.2 ± 2.3 -2 -12
Δ Isoproteronol -9.6 ± 5 0.9 ± 2.2 -6 -2
Nasal potential difference measurements, patient's left nare Figure 1
Nasal potential difference measurements, patient's 
left nare. Patients with cystic fibrosis can be differentiated 
from controls by the measurement of nasal potential differ-
ences (NPD). In this study, nasal potential differences were 
measured using a standardized operating procedure that was 
developed by a Cystic Fibrosis Foundation clinical trials net-
work to be followed by all sites that perform collaborative 
studies [1].Journal of Medical Case Reports 2008, 2:176 http://www.jmedicalcasereports.com/content/2/1/176
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These patients are typically diagnosed with CF later in
childhood, as the cases are clinically less severe and usu-
ally lack sinopulmonary disease.
Pancreatitis is a rare manifestation of cystic fibrosis, affect-
ing < 2% of patients with CF. The incidence of sympto-
matic pancreatitis in patients with cystic fibrosis has been
shown to be only 1–2%. A minority of patients with CF
(13–15%) express the pancreatic sufficient phenotype.
These patients are known to carry a greater risk of pancre-
atitis and have genotypes causing less severe loss of func-
tion. Over 1000 CFTR mutations have been identified and
have been archived on an online database. [2] About half
of patients with CF in the United States are ΔF508
homozygotes, and another 40% are compound heterozy-
gotes, who have one ΔF508 allele plus one less common
CF- allele. Mutations in Class 1, 2 (ΔF508), or 3 are severe
and associated with pancreatic insufficiency. Compound
heterozygotes with a mild Class 4 or 5 mutations, unlike
ΔF508 homozygotes, typically have pancreatic sufficiency
and are frequently diagnosed at an older age due to the
milder phenotypic presentation and lack of suspicion for
the diagnosis. Multiple cystic fibrosis gene mutations are
associated with chronic pancreatitis, including the rare
L997F mutation found in our patient [3,4].
The L997F (missense substitution of leucine with pheny-
lalanine at position 997) is a highly conserved residue in
transmembrane domain 9. Both heterozygosity for L997F
and compound heterozygosity for other CFTR mutations
have been associated with idiopathic disseminated bron-
chiectasis, recurrent pancreatitis, and hypertrypsinemia in
infants. L997F was identified in 4 (12.5%) out of 32
patients with idiopathic pancreatitis, and in 4 (8%) of 49
infants with hypertrypsinemia. Among the 4 patients with
recurrent pancreatitis, just one was a compound heterozy-
gote (L997F/ΔF508). The others included one L997F/5T,
and two with L997F/no mutation. In this same study,
among the mothers of these children with CF who had
recurrent pancreatitis or hypertrypsinemia, most were
found to be carriers of ΔF 508 gene mutations. Interest-
ingly, none of the mothers carried the L997F mutation
[5,6]. According to the CF Consensus Statement from
1998, these studies would support categorizing L997F as
a "CF-causing mutation" associated with the increased
probability of acquiring pancreatic ductular obstruction
and an increased risk for recurrent pancreatitis, despite
normal sweat chloride testing [7].
In another study of 14 adults diagnosed with idiopathic
chronic pancreatitis or recurrent acute pancreatitis, the
L997F mutation was identified in 3 patients. [4] On the
other hand, one report disputed the association, describ-
ing a case of homozygosity for L997F in a child with a nor-
mal clinical phenotype, normal sweat test, and normal
intestinal chloride transport [8]. A recent case report iden-
tified a 5 year-old Pakistani child with cystic fibrosis and
high sweat chloride levels who was found to have the
L997F mutation. That patient had symptoms compatible
with CF without a history of chronic recurrent pancreatitis
[9].
In our patient, the availability of nasal transepithelial
potential difference measurements ultimately led to the
clinical suspicion of compound heterozygosity for the CF
mutation. Respiratory epithelium, including nasal epithe-
lium, regulates the transport of ions such as sodium (Na+)
and chloride (Cl-). Because of the abnormal Cl- transport
in CF, nasal potential difference (PD) measurements in
these patients reveal a different pattern than in patients
without the disease. Three features distinguish CF from
controls: 1) higher basal PD, reflecting enhanced Na+
transport secondary to relative Cl-  impermeability 2)
greater inhibition of PD after nasal perfusion with amilo-
ride, a Na+ channel inhibitor, and 3) little or no change in
change of Cl- transport in response to perfusion with a Cl-
-free solution along with isoproteronol, (which reflects an
absence of CFTR-mediated Cl- secretion). Particularly, the
chloride secretory response to chloride free and isoproter-
onol has high sensitivity and specificity for normal versus
CF or atypical CF. [10] This method has increased the abil-
ity to detect patients with compound heterozygous CF,
which can present more atypically.
Patients with compound heterozygous CF gene muta-
tions, unlike ΔF508 homozygotes, typically have pancre-
atic sufficiency and are frequently diagnosed at an older
age due to the absence of overt pulmonary symptomatol-
ogy. In these patients, sweat chloride levels are often nor-
mal and nasal potential differences may also show only
subtle perturbation in normal CFTR function, as was dem-
onstrated in our patient. As commercial genetic testing for
extended CFTR mutation analysis is now available, it is
important to suspect a CFTR mutation in a patient with
idiopathic chronic pancreatitis.
Interestingly, our patient was diagnosed with pancreas
divisum prior to being diagnosed with cystic fibrosis. It is
known that pancreas divisum is found in the healthy gen-
eral population with a prevalence of 5–10%[11]. Why cer-
tain patients with pancreas divisum develop pancreatitis
and not others is not known. One study has suggested a
link between CFTR dysfunction and recurrent acute pan-
creatitis in patients with pancreas divisum. In this study,
among those patients with recurrent pancreatitis and pan-
creatic divisum, the nasal evoked potentials were interme-
diate between those healthy patients and those with overt
CF [12]. In another study comparing incidence of CFTR
mutations between patients with pancreatitis and controls
undergoing ERCP, 22% of patients with pancreatitis andJournal of Medical Case Reports 2008, 2:176 http://www.jmedicalcasereports.com/content/2/1/176
Page 4 of 4
(page number not for citation purposes)
pancreas divisium had a CFTR mutation compared with
0% of controls with pancreas divisum [13]. The combina-
tion of pancreatic divisum and abnormal CFTR function
may contribute to the severity and frequency of recurrent
pancreatitis. The treatment of recurrent pancreatitis with
sphincterotomy and stent placement is controversial. The
benefit of minor papillotomy and stent placement in
patients with pancreatic divisum is controversial with a
high rate for necessary reintervention. In a retrospective
review of the largest experience reported to date of endo-
scopic therapy for pancreas divisum at a referral center,
two types of sphincterotomy procedures were compared,
needle-knife sphincterotomy (NKS) and the standard
pull-type sphincterotomy (PTS). The reintervention rate
was similar for both at 29 and 26% respectively. It is not
clear whether the need for reintervention was secondary
to a high rate of stenosis or if the pancreas divisum was
not the underlying cause for the pancreatitis [14].
Our patient had no response to sphincterotomy. The com-
bination of dietary management and pancreatic enzyme
supplementation reduced the frequency of pancreatitis
paroxysms. Unfortunately, our patient shows radiological
signs of chronic pancreatitis, despite therapy. All of these
measures were implemented to improve our patient's
quality of life. Furthermore, this child's diagnosis ulti-
mately led to genetic testing of her 4 siblings that ulti-
mately led to the identification of 3 CF gene mutation
carriers.
Conclusion
Chronic or recurrent pancreatitis in children should raise
suspicion for CFTR mutations, despite a normal sweat test
or the presence of an existing diagnosis of pancreas
divisum. Since CFTR mutation analysis has become com-
mercially available, we anticipate that the number of idi-
opathic pancreatitis patients in pediatrics should
decrease. Among patients with pancreatic divisum refrac-
tory to sphincterotomy, identification of the coexistence
of CFTR dysfunction may facilitate a more practical thera-
peutic approach, including dietary modification, pancre-
atic enzyme supplementation and close clinical follow-
up.
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